FABP Biotech

FABP Biotech

Biotechnology-Research

Rio de Janeiro, RJ
Brazil
Website
www.fabpbiotech.com.br
Company Tagline

Safe, effective, and environmentally-friendly solutions to problems caused by veterinary parasitic infections.

Industry Category
Biotechnology-Research
Business Keywords
Veterinary Vaccines Anti-helminth Vaccines Animal Health Biotechnology Research Fasciolosis Prevention Heartworm Vaccine Sm14 Technology Dirofilaria immitis veterinary parasites heartworm fasciolosis vaccines Fasciola hepatica
Company Description

FABP Biotech is dedicated to providing safe, effective, and environmentally-friendly solutions to veterinary parasitic infections. Located in Rio de Janeiro, RJ, at Rua Lasar Segall, FABP Biotech specializes in biotechnology research, focusing on the development of innovative anti-helminth vaccines for animal use.

Operating as a spin-off of the Oswaldo Cruz Foundation, FABP Biotech leverages the Brazilian Technological Innovation Law to advance its research and development efforts. The company holds exclusive licensing of patents and rights for the final development, registration, and commercialization of vaccines and veterinary products based on Sm14, a Fatty Acid Binding Protein known for eliciting a robust immune response in animals with helminth infections.

FABP Biotech is currently exploring Sm14 technology in two primary areas: LIVAC ®, a Sm14 vaccine to prevent fasciolosis in livestock, and Sm14PET, a Sm14 vaccine targeting worms that affect pets, such as heartworm. These initiatives underscore FABP Biotech's commitment to creating cutting-edge solutions for animal health. We invite the manager of FABP Biotech to create a customized and exclusive company showcase and product listing on our platform.

A FABP Biotech se dedica a fornecer soluções seguras, eficazes e ecologicamente corretas para infecções parasitárias veterinárias. Localizada no Rio de Janeiro, RJ, na Rua Lasar Segall, a FABP Biotech é especializada em pesquisa biotecnológica, com foco no desenvolvimento de vacinas anti-helmínticas inovadoras para uso animal.

Operando como um spin-off da Fundação Oswaldo Cruz, a FABP Biotech aproveita a Lei Brasileira de Inovação Tecnológica para impulsionar seus esforços de pesquisa e desenvolvimento. A empresa detém o licenciamento exclusivo de patentes e direitos para o desenvolvimento final, registro e comercialização de vacinas e produtos veterinários baseados em Sm14, uma Proteína de Ligação de Ácidos Graxos conhecida por provocar uma resposta imune robusta em animais com infecções por helmintos.

A FABP Biotech está atualmente explorando a tecnologia Sm14 em duas áreas principais: LIVAC ®, uma vacina Sm14 para prevenir a fasciolose em animais de pecuária, e Sm14PET, uma vacina Sm14 direcionada a vermes que afetam animais de estimação, como o verme do coração. Estas iniciativas sublinham o compromisso da FABP Biotech em criar soluções de ponta para a saúde animal. Convidamos o gestor da FABP Biotech a criar uma apresentação de empresa e listagem de produtos personalizada e exclusiva na nossa plataforma.

Key Personnel / Employees
Teresa Gurgel Celso Raul Romero Ramos Dr. Angela Demaree Miryam Marroquin

Similar Companies

Other organizations in the same industry

GlucoSense Inc
Biotechnology-Research

Helping Type 1 & Type 2 Diabetics Live Healthier, Stress-free Lives.

Atlanta, Georgia
United States
View Profile
HCell Inc.
Biotechnology-Research
Austin, TX
United States
View Profile
Stealth Biotech Development
Biotechnology-Research

A strategic approach adopted by a company to keep its activities, products, or services confidential...

View Profile
Microbe Investigations Switzerland (MIS)
Biotechnology-Research

Swiss CRO and Testing Lab

View Profile

Alternative Company Names

This company is also known as

FABP Biotech